Arbuckle Stuart A's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Aug 17, 2022
- Accession no.
- 0000899243-22-029030
- Filed
- Aug 17, 2022
- Trade date
- Aug 15, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.74M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Arbuckle Stuart ACIK 0001557290 | Officer (EVP, COO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2022 | Common Stock | MOption exerciseAcquired | +6,571 | $155.57 | +$1,022,250.47 | 67,451 | Direct | |
| Aug 15, 2022 | Common Stock | SSaleDisposed | −1,254 | $300.30F2,F3 | −$376,576.2 | 66,197 | Direct | |
| Aug 15, 2022 | Common Stock | SSaleDisposed | −4,242 | $301.61F2,F4 | −$1,279,429.62 | 61,955 | Direct | |
| Aug 15, 2022 | Common Stock | SSaleDisposed | −400 | $302.55F2,F5 | −$121,020 | 61,555 | Direct | |
| Aug 15, 2022 | Common Stock | SSaleDisposed | −2,339 | $303.78F2,F6 | −$710,541.42 | 59,216 | Direct | |
| Aug 15, 2022 | Common Stock | SSaleDisposed | −6,990 | $304.67F2,F7 | −$2,129,643.3 | 52,226 | Direct | |
| Aug 15, 2022 | Common Stock | SSaleDisposed | −6,948 | $305.38F2,F8 | −$2,121,780.24 | 45,278 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2022 | Common Stock | MOption exerciseDisposed | −6,571 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the Issuer or a security holder of the Issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 6 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $300.30 (range $300.00 to $300.73).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $301.61 (range $301.09 to $302.01).
Referenced by the price of 1 transaction in Table I.
- F5
Open market sales reported on this line occurred at a weighted average price of $302.55 (range $302.13 to $302.90).
Referenced by the price of 1 transaction in Table I.
- F6
Open market sales reported on this line occurred at a weighted average price of $303.78 (range $303.13 to $304.09).
Referenced by the price of 1 transaction in Table I.
- F7
Open market sales reported on this line occurred at a weighted average price of $304.67 (range $304.13 to $305.12).
Referenced by the price of 1 transaction in Table I.
- F8
Open market sales reported on this line occurred at a weighted average price of $305.38 (range $305.13 to $305.83).
Referenced by the price of 1 transaction in Table I.